Join to View Full Profile
400 E Jamie Ct"# Myokardi"South San Francisco, CA 94080
Phone+1 650-741-0902
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jonathan Fox, MD is a cardiologist in South San Francisco, California.
Education & Training
Duke University HospitalFellowship, Cardiovascular Disease, 1990 - 1993- Duke University HospitalResidency, Internal Medicine, 1987 - 1990
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1987
Publications & Presentations
PubMed
- 3 citationsLong-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.Daniel P Judge, Julian D Gillmore, Kevin M Alexander, Amrut V Ambardekar, Francesco Cappelli
Circulation. 2025-03-04 - Comparison of in-clinic assessment of 6MWT by conventional method and using wearable sensors for patients with ATTR-CM.Prem Soman, Michel G Khouri, Daniel Lenihan, Alex Reyentovich, Brett W Sperry
Future Cardiology. 2025-02-01 - 1 citationsEffect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Subs...Yousuf Razvi, Daniel P Judge, Ana Martinez-Naharro, Adam Ioannou, Lucia Venneri
Circulation. Heart Failure. 2024-12-01
Press Mentions
Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid CardiomyopathyNovember 11th, 2018
Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis CardiomyopathyMay 3rd, 2018
